Canada markets closed

AEON Biopharma, Inc. (AEON)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.7300+0.0700 (+4.22%)
At close: 04:00PM EDT
1.6500 -0.08 (-4.62%)
After hours: 07:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.6600
Open1.6800
Bid1.6500 x 2900
Ask1.8300 x 1100
Day's Range1.6200 - 1.7400
52 Week Range1.3800 - 17.1700
Volume71,027
Avg. Volume93,780
Market Cap67.094M
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.3600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • GlobeNewswire

    AEON Biopharma Provides Update on Development Pipeline

    Includes two late-stage clinical programs and two early-stage clinical programsIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our ear

  • GlobeNewswire

    AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

    – Trial did not meet primary endpoint –IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet t